Presence of a malabsorption syndrome, gastrointestinal disorder, or gastrointestinal surgery that could affect the absorption of pazopanib
Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib
Gastrointestinal malabsorption, or any other condition that in the opinion of the investigator might affect the absorption of the study drug.
Malabsorption syndrome or other gastrointestinal illness that could affect oral absorption of study drugs
Has gastrointestinal conditions that could affect the absorption of DS-b in the opinion of the Investigator.
Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib or everolimus
Presence of gastrointestinal disease that would significantly affect compound absorption.
Presence of a gastrointestinal condition that may affect drug absorption
Gastrointestinal malabsorption or any other condition in the opinion of the investigator that might affect the absorption of lenvatinib
Subjects with significant gastrointestinal abnormalities that may affect absorption (e.g., gastric bypass, short gut syndrome).
Has presence of a gastrointestinal condition that may affect drug absorption
Prior surgery or gastrointestinal dysfunction that may affect drug absorption (e.g., gastric bypass surgery, gastrectomy)
Presence of a malabsorption syndrome, gastrointestinal disorder, or gastrointestinal surgery that could affect the absorption of axitinib
Malabsorption syndrome or other gastrointestinal (GI) illness that could affect oral absorption of the study drug
Previous bowel resection anticipated to affect drug absorption
Patients with gastrointestinal impairment that would affect the absorption of enzalutamide or previous history of colitis
Subjects with gastrointestinal conditions that could affect the absorption of DS-b in the opinion of the investigator
Inability to take medication orally, dysphagia or an active gastric ulcer resulting from previous surgery or a severe gastrointestinal disease,or any other condition that investigators believe may affect absorption of the investigational product;
Any gastrointestinal (GI) disorder that may affect absorption of oral medications, such as mal-absorption syndrome or status post major bowel resection
Gastrointestinal abnormality that would affect absorption of SGN-FF
A gastrointestinal disorder that may affect the absorption of study medication.
Gastrointestinal malabsorption or any other condition that in the opinion of the investigator might affect the absorption of lenvatinib.
Prior surgery or gastrointestinal dysfunction that may affect drug absorption (e.g, gastric bypass surgery, gastrectomy)
Gastrointestinal diseases or conditions that could affect drug absorption or could alter the assessment of safety
Gastrointestinal diseases or conditions that could affect drug absorption
Prior surgery or gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypass surgery, gastrectomy)
Prior surgery or gastrointestinal dysfunction that may affect drug absorption (e.g., gastric bypass surgery, gastrectomy)
Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib
Subjects with gastrointestinal abnormalities including inability to take oral\n             medication, malabsorption or other conditions like chronic inflammatory bowel disease\n             that may affect absorption.
Or any condition that might affect the absorption of orally taken medication
History of a gastrointestinal condition that in the opinion of the Investigator may affect oral drug absorption.
History of gastrointestinal condition that may affect drug absorption.
known gastrointestinal disease or condition which may affect the absorption of ASN;
Gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib in the opinion of the investigator
Patients with gastrointestinal comorbidities that would affect intake or absorption of ponatinib
Have malabsorption syndrome or other GI illness that could affect oral absorption of the study drug.
Gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass.
Prior surgery or gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypass surgery, gastrectomy)
Presence of active gastrointestinal (GI) disease or other condition that could affect gastrointestinal absorption (e.g. malabsorption syndrome) or predispose a subject to GI ulceration; subjects with prior Whipple procedure are eligible
Gastrointestinal malabsorption or any other condition in the opinion of the investigator that might affect the absorption of lenvatinib.
Have malabsorption syndrome or other gastrointestinal illness that could affect absorption of ponatinib
Gastrointestinal conditions that could affect drug absorption including post surgical states such as gastric bypass
Any malabsorption condition which, in the opinion of the treating physician, will affect the absorption of any of the agents used in this study.
Gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass.
Clinically significant gastrointestinal abnormalities that may affect absorption of investigational products
Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product.
Gastro-intestinal abnormalities that could affect the absorption of study drug.
Clinically significant gastrointestinal abnormality that would affect absorption of the drug
Gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass.
Gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass.
Clinically significant GI abnormalities that may affect absorption of investigational product.
Gastrointestinal conditions that may significantly affect the absorption of regorafenib
Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib or everolimus
History or current evidence of gastrointestinal malabsorption which, in the opinion of the investigator, may affect the extent of absorption of pritelivir.
Gastrointestinal malabsorption or any other condition that in the opinion of the investigator might affect the absorption of study drug.